Caitlin Kelly
Acute Care · Saint Clair Shores, MINPI 1629581970
Payments from drug & device makers
Across 80 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$251
- Aurinia Pharma U.S., Inc.$208
- AstraZeneca$190
- Mallinckrodt Hospital Products Inc.$147
- Calliditas Therapeutics US Inc.$134
- Amgen$87
- plus $477 from 14 others
What the payments were for
- Food & beverage$1,45697%
- Education$393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 15 | $251 |
| Aurinia Pharma U.S., Inc. | 10 | $208 |
| AstraZeneca(2 entities) | 11 | $190 |
| Mallinckrodt Hospital Products Inc. | 8 | $147 |
| Calliditas Therapeutics US Inc. | 6 | $134 |
| Amgen | 5 | $87 |
| ANI Pharmaceuticals, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Travere Therapeutics, Inc. | 4 | $47 |
| Novartis | 2 | $42 |
| OPKO Pharmaceuticals, LLC | 2 | $35 |
| Vifor Pharma, Inc. | 1 | $32 |
| Boehringer Ingelheim | 1 | $26 |
| Ardelyx, Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $23 |
| Akebia Therapeutics Inc | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
How this compares
$1,495 in reported general payments places this provider in the 80th percentile of 567 acute care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 13 | $9,678 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $9,130 |
| Tacrolimus | 14 | $1,378 |
| Bumetanide | 27 | $1,064 |
| Sodium Polystyrene Sulfonate | 13 | $911 |
| Nifedipine ErNifedipine | 15 | $838 |
| Calcitriol | 33 | $611 |
| Torsemide | 24 | $497 |
| Losartan Potassium | 34 | $388 |
| Doxazosin Mesylate | 12 | $299 |
| Mycophenolate Mofetil | 14 | $290 |
| Carvedilol | 28 | $282 |
| Hydralazine Hcl | 20 | $279 |
| Amlodipine Besylate | 22 | $243 |
| Lisinopril | 19 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $190 | $18,80826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 567 acute care providers in Michigan.
Other acute care in Saint Clair Shores
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Andrew PalmerLansing$9K
- Angela BrennanDearborn Heights$7K
- Jennifer RutzenLansing$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.